The form was uploaded to medical-data-models.org - Original URL: https://medical-data-models.org/30593
StudyName: Eligibility Metastatic Breast Cancer NCT00696072
Date of export from the portal: 02.07.2020
Copyright Holder: See clinicaltrials.gov
Date of Upload / last change: 17.06.2018
License: Creative Commons BY 4.0

----

Description: 
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic; ODM derived from: https://clinicaltrials.gov/show/NCT00696072
